Paolo A. Ascierto
A5029398339- Cancer Immunotherapy and Biomarkers
- Melanoma and MAPK Pathways
- CAR-T cell therapy research
- Cutaneous Melanoma Detection and Management
- Immunotherapy and Immune Responses
- Colorectal Cancer Treatments and Studies
- Diabetes Treatment and Management
- Cancer Genomics and Diagnostics
- Computational Drug Discovery Methods
- Pancreatic and Hepatic Oncology Research
- Click Chemistry and Applications
- HER2/EGFR in Cancer Research
- Nonmelanoma Skin Cancer Studies
- Immune Cell Function and Interaction
- Peptidase Inhibition and Analysis
- Immune cells in cancer
- Synthesis of Tetrazole Derivatives
- Neutropenia and Cancer Infections
- Monoclonal and Polyclonal Antibodies Research
- Synthesis and biological activity
- Advanced Breast Cancer Therapies
- Protein Degradation and Inhibitors
- COVID-19 Clinical Research Studies
- Brain Metastases and Treatment
- Biosimilars and Bioanalytical Methods
Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"
2016-2025
Maastricht University
2024
Medisch Spectrum Twente
2024
Molecular Oncology (United States)
2024
Leiden University Medical Center
2024
University Medical Center Utrecht
2024
Cornell University
2013-2024
Memorial Sloan Kettering Cancer Center
2011-2024
Merck Serono (Switzerland)
2024
MSD K.K. (Japan)
2024
Nivolumab (a programmed death 1 [PD-1] checkpoint inhibitor) and ipilimumab cytotoxic T-lymphocyte–associated antigen 4 [CTLA-4] have been shown to complementary activity in metastatic melanoma. In this randomized, double-blind, phase 3 study, nivolumab alone or plus was compared with patients
Phase 1 and 2 clinical trials of the BRAF kinase inhibitor vemurafenib (PLX4032) have shown response rates more than 50% in patients with metastatic melanoma V600E mutation.
Nivolumab was associated with higher rates of objective response than chemotherapy in a phase 3 study involving patients ipilimumab-refractory metastatic melanoma. The use nivolumab previously untreated advanced melanoma has not been tested controlled study.We randomly assigned 418 who had without BRAF mutation to receive (at dose mg per kilogram body weight every 2 weeks and dacarbazine-matched placebo weeks) or dacarbazine 1000 square meter body-surface area nivolumab-matched weeks)....
Nivolumab combined with ipilimumab resulted in longer progression-free survival and a higher objective response rate than alone phase 3 trial involving patients advanced melanoma. We now report 3-year overall outcomes this trial.
Nivolumab plus ipilimumab or nivolumab alone resulted in longer progression-free and overall survival than a trial involving patients with advanced melanoma. We now report 5-year outcomes the trial.
Genomes of tumors that are deficient in DNA mismatch repair (dMMR) have high microsatellite instability (MSI-H) and harbor hundreds to thousands somatic mutations encode potential neoantigens. Such therefore likely be immunogenic, triggering upregulation immune checkpoint proteins. Pembrolizumab, an anti‒programmed death-1 monoclonal antibody, has antitumor activity against MSI-H/dMMR cancer. We report data from the phase II KEYNOTE-158 study pembrolizumab patients with previously treated,...
Nivolumab and ipilimumab are immune checkpoint inhibitors that have been approved for the treatment of advanced melanoma. In United States, has also as adjuvant therapy melanoma on basis recurrence-free overall survival rates were higher than those with placebo in a phase 3 trial. We wanted to determine efficacy nivolumab versus patients resected this randomized, double-blind, trial, we randomly assigned 906 (≥15 years age) who undergoing complete resection stage IIIB, IIIC, or IV receive an...
The combined inhibition of BRAF and MEK is hypothesized to improve clinical outcomes in patients with melanoma by preventing or delaying the onset resistance observed inhibitors alone. This randomized phase 3 study evaluated combination inhibitor vemurafenib cobimetinib.We randomly assigned 495 previously untreated unresectable locally advanced metastatic V600 mutation-positive receive cobimetinib (combination group) placebo (control group). primary end point was investigator-assessed...
The programmed death 1 (PD-1) inhibitor pembrolizumab has been found to prolong progression-free and overall survival among patients with advanced melanoma. We conducted a phase 3 double-blind trial evaluate as adjuvant therapy in resected, high-risk stage III melanoma.Patients completely resected melanoma were randomly assigned (with stratification according cancer geographic region) receive 200 mg of (514 patients) or placebo (505 intravenously every weeks for total 18 doses (approximately...
On the basis of data from a phase 2 trial that compared checkpoint inhibitor ipilimumab at doses 0.3 mg, 3 and 10 mg per kilogram body weight in patients with advanced melanoma, this evaluated dose who had undergone complete resection stage III melanoma.After cutaneous we randomly assigned them to receive (475 patients) or placebo (476) every weeks for four doses, then months up years until disease recurrence an unacceptable level toxic effects occurred. Recurrence-free survival was primary...
Lymphocyte-activation gene 3 (LAG-3) and programmed death 1 (PD-1) are distinct inhibitory immune checkpoints that contribute to T-cell exhaustion. The combination of relatlimab, a LAG-3-blocking antibody, nivolumab, PD-1-blocking has been shown be safe have antitumor activity in patients with previously treated melanoma, but the safety untreated melanoma need investigation.In this phase 2-3, global, double-blind, randomized trial, we evaluated relatlimab nivolumab as fixed-dose compared...